Markers of Oxidative Stress in a Early Week Miscarriage: Ischemia of Modified Albumin — IMA  

First Trimester Pregnancy Clinical Trial

Official title: Markers of Oxidative Stress in a Early Week Miscarriage: Ischemia of Modified Albumin

Status Recruiting

Clinical Trial Summary

The finding that ischemia-modified albumin (IMA) is increased in pre-eclamptic pregnancy suggests a role for IMA as a potential biomarker for abnormal placental development related to miscarriage.This study was undertaken to evaluate IMA levels in women with recurrent pregnancy loss (RPL).

Clinical Trial Description

Ischemia-modified albumin (IMA) measured by the albumin cobalt binding test is a relatively new biomarker in the identification of myocardial ischemia. Experimental studies have shown that pregnancies normally develop in a relatively hypoxic intrauterine environment, and the subsequent reperfusion and oxidative stress is important for physiological trophoblast development. The finding that maternal serum IMA levels are raised so early in pregnancy provides further support for IMA as a potential marker for abnormal placental development that may be related to early pregnancy loss. In this study, we aimed to evaluate maternal circulating IMA levels in women with RPL by comparing them with healthy controls. ;

Study Design

Observational Model: Case-Only, Time Perspective: Cross-Sectional

Related Conditions & MeSH terms

• Absence of Fetal Pole on Ultrasonographic Examination.
• Fetal Heart Activity Absent
• First Trimester Pregnancy

• NCT number: NCT01988740
• Study type: Observational
• Source: Bakirkoy Dr. Sadi Konuk Research and Training Hospital
• Contact: hediye dagdeviren, md
• Phone: 5079872463
• Email: hediyedagdeviren@gmail.com
• Status: Recruiting
• Phase: N/A
• Start date: November 2013
• Completion date: April 2014